Showing results (501-510 of 716) with videos related to

Sort By:
Pageof 72
Annals of Clinical and Translational Neurology|January 19, 2022
Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19Alexandra C Apple, Alexis Oddi, Michael J Peluso, et al.
Journal of Neurovirology|February 2, 2021
Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patientsJoanna Hellmuth, T Allen Barnett, Breton M Asken, et al.
Molecular Therapy. Methods & Clinical Development|September 20, 2019
HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral TherapyYinyan Xu, Ilana M Trumble, Joanna A Warren, et al.
International Journal of Behavioral Medicine|December 17, 2021
Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and RecoveryEdda I Santiago-Rodriguez, Andres Maiorana, Michael J Peluso, et al.
Science (New York, N.Y.)|January 18, 2024
Impact of HLA class I functional divergence on HIV controlMathias Viard, Colm O'hUigin, Yuko Yuki, et al.
Frontiers in Immunology|September 13, 2021
HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral SuppressionKai Kammers, Athena Chen, Daniel R Monaco, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Epstein Barr viral shedding dynamics in saliva during acute SARS-CoV-2 infectionMiguel A Garcia-Knight, Jessica Y Chen, Amethyst Zhang, et al.
The Journal of Clinical Investigation|April 23, 2024
Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1Gregory D Whitehill, Jaimy Joy, Francesco E Marino, et al.
Frontiers in Immunology|January 23, 2026
Contrasting immune responses in COVID-19: insights from healthcare workers and infected patients on plasmablast, pDC, and NK cell dynamicsLaura Martín-Pedraza, Eulalia Rodríguez-Martín, Erick De La Torre-Tarazona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2025
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)Sergio Serrano-Villar, Laura Martín-Pedraza, Juan Tiraboschi, et al.
Pageof 72